Boule Diagnostics ABOMXSTO: BOUL

BOUL: Sales declined but margins improved; restructuring aims to boost profitability

· Issued by Boule Diagnostics AB

Q2 2024 saw a 2.5% sales decline but improved gross margin to 43.1%. Adjusted operating profit rose, though non-recurring costs led to a net loss. Strategic restructuring and cost optimization are underway to enhance margins and efficiency.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Boule Diagnostics AB on 6ix

In the deck

Later from Boule Diagnostics

All Boule Diagnostics news releases